The Salk Institute for Biological Studies

The University of Sydney

Mitobridge, Inc.

Thomas J Baiga

Ronald Mark Evans

Michael Downes

John F W Keana

Joseph Noel

Christopher Liddle

Ruth T Yu

Annette R Atkins

Jae Myoung Suh

Sungsoon Fang

Mark G Bock

Mike A Patane

Weiwei Fan

Emi Kanakubo Embler

Arthur F Kluge

David R Schubert

Andrew Dillin

Yuanbin Liu

John Fw Keana

Justin Ramsey

Erik Kapernick

Authur F Kluge

John FW Keana

Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.

Analogs of fexaramine and methods of making and using

Provided herein are compounds and compositions useful in increasing PPAR&#x3b4; activity. The compounds and compositions provided herein are useful for the treatment of PPAR&#x3b4; related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

PPAR agonists

Novel FXR agonists are disclosed, embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.

FXR agonists and methods for making and using

Disclosed herein is a method for synthesizing terpenoid compounds, as well as compositions comprising terpenoids and methods for their use. In one aspect the process is represented by the scheme   and

Method for making terpene derivatives

The disclosure provides methods and compositions useful for screening inhibitors of aggregation mediated proteotoxicity. The disclosure provides transgenic animals and cell useful for such screening. Also provided are compounds useful for inhibiting aggregation mediated proteotoxicity in a subject.

Methods for screening and compounds that protect against amyloid diseases

In accordance with the present invention, there are provided novel compounds that protect neurons and/or promote neuroregeneration and/or promote memory formation. Such compounds are useful for treatment of a variety of neural disorders and conditions. In another aspect of the present invention, there are also provided formulations containing one or more of the above-described compounds, optionally further containing additional neurologically active compound(s) and/or adjuvants to facilitate delivery thereof across the blood/brain barrier. In still another aspect of the present invention, there are further provided methods for treating a wide variety of neurological indications, e.g., acute neural injuries, chronic injuries, promoting memory formation, and the like.

Methods for treating neural disorders and conditions, and compounds useful therefor

Growing community of inventors

Escondido, CA, United States of America

Thomas J Baiga